Seamless interlinking: How risk management and clinical evaluation go hand in hand

In this blog post you will learn how to transfer identified hazards from risk management to targeted clinical issues, which regulatory requirements of the MDR and relevant ISO standards you have to consider, how to link the benefit-risk analyzes with clinical evidence and derive the clinical data requirement-from the risk management acts to clinical evaluation Report - for a complete traceability are essential, which practice -oriented approaches and best practices promote smooth interdisciplinary cooperation, how they recognize and bypass typical stumbling blocks at an early stage and what outlook there are on further interfaces in product development and post -market surveillance.

Abbreviations

MDR	Medical Device Regulation (EU Ordinance 2017/745)
Sota	State of the Art (state of the art)
CEP	Clinical evaluation plan
CERIUM	Clinical Evaluation Report
Pmcf	Post-Market Clinical Follow-up
Pms	Post-Market Surveillance

Underlying regulations and norms

EU Regulation 2017/745 (MDR)

En ISO 14971

1 Introduction

The tightened requirements of the MDR make a close integration of all processes essential. In particular, the interface between risk management and clinical evaluation plays a crucial role: Only if identified risks are consistently transferred to clinical issues, reliable benefit -risk analyzes can be created and the actual data requirement for the CLINical Evaluation Report (CER) can be derived precisely.

2. Basic terms and process overview

2.1 Definition of risk management
Risk management is a systematic, documented and continuous cycle for identification, evaluation, control and surveillance of risks that can arise from a medical device. All potential hazards along the entire product life cycle - from development to production to application and disposal - are recorded. According to ISO 14971, the process includes risk analysis (identification and assessment of severity and probability of occurrence), the risk assessment (determination of acceptable risk -ending), the risk control (definition and implementation of measures) and the review of the effectiveness of these measures. All steps are documented in the risk management acts and regularly updated as part of reviews and change control processes.

2.2 Definition of clinical evaluation
The clinical evaluation is an interdisciplinary process that systematically combines all available clinical data into a medical device, evaluating and draws conclusions on safety and performance. It forms a central interface at numerous other processes, such as design verification, usability, post -market surveillance and vigilance. The aim is to demonstrate through a structured benefit -risk analysis that the expected benefit of the product clearly outweighs the remaining risks. The results are documented in the Clinical Evaluation Report (CER) and serve as a key to key to named points and authorities.

2.3 Process map: From risk analysis to clinical evaluation
The transition from risk management to clinical evaluation can be divided into three phases:

1. Risk analysis and prioritization
• Identification of hazards: Systematic recording of all potential risks along the product life cycle (design, production, application, disposal).
• Severe grade and occurrence: Assessment of how serious damage would be and how likely his appearance is.
2. Derivation of clinical issues
• Risk -to -evidence mapping: Every risk classified as critically is translated into one or more clinical questions. Example: A high risk of thrombosis in an implantable device leads to the question of whether the thrombosis rate in clinical studies falls below acceptable limit values.
• Determination of the data requirement: What type of clinical data (e.g. study data, registry analyzes, real -world -evidence) are needed to reliably evaluate the risk?
3. Integration into the clinical evaluation
• Benefit -Risk analysis: merging of the risk assessment with the clinical benefit; Representation that the expected benefit predominates the remaining risks by far.
• Documentation in the CER: Structured proof that all identified risks were addressed and occupied by clinical evidence. Cross -references to risk management clocks ensure traceability.

This process map makes it clear that risk management and clinical evaluation are not isolated disciplines, but contribute closely to the common goal: the market approval of a secure and effective medical device.

3. Interface: Risk management → clinical evaluation

3.1 Derivation of the claims for clinical security from clinically relevant risks

What are clinically relevant risks?

Clinically relevant risks are the potential hazards that can affect health, security or well -being of patients directly and specifically (e.g. tissue damage, infection ...).

Proceed

Every risk identified in risk management is first recorded in the risk analysis and evaluated in terms of severity and probability of appearance.

Clinically relevant risks identified in risk management are systematically translated into checkable clinical questions. Clinically relevant risks from risk analysis should be covered with one or more claim/endpoints for clinical security.

In essence, it is about systematically transferring clinically relevant risks from the risk management acts to the clinical evaluation and providing clinical evidence there. The process is divided into four steps:

a) Identification of clinically relevant residual risks
from the risk management acts are listed all damage that can specifically threaten the patient (e.g. tissue trauma, infection, false alarm, data loss). These residual risks form the starting point for the clinical evaluation.

b) Translation into clinical endpoints
for each residual risk is defined or several measurable endpoints are defined, which are recorded in the Clinical Evaluation Plan (CEP). An end point describes precisely how the respective risk is recorded objectively (e.g. incidence rate of irritation, percentage carried out cleaning processes without microbial detection, number of incorrect alarms per 100 h operation).

c) Definition of the evidence strategy
according to the three routes of the clinical evaluation Select the appropriate data source:

1. Own clinical studies for direct, prospective data on the product
2. Equivalence or literature literature on comparable systems
3. Performance and in -vitro tests or PMCF if clinical studies are not suitable.
4. For each endpoint, you determine which study designs, sample circumference or test protocols are required to make valid statements.

d) Documentation and Benefit -Risk analysis in the CER
- Tabular overview: Change the end points, data sources and main results in tables.
- narrative sections: Explain how the results achieved minimize the respective residual risk.
- Benefit -Risk table: Show clearly that the expected clinical benefit clearly predominates the remaining risks.
- Traceability: In every CER section, refer to the corresponding risk in risk management clocks to ensure complete traceability.

This procedure ensures that every risk management defined in risk management systematically addressed, documented with a suitable evidence and evaluated positively in the benefit -risk ratio. This forms the basis for convincing admission documentation and long -term patient safety.

3.2 Linking of benefit/risk analysis with clinical evidence
The benefit/risk analysis forms the core of the Clinical Evaluation Report (CER) and links the residual risks defined in risk management with the data collected as part of the clinical evaluation. The aim is to prove through a systematic representation that the expected clinical benefit predominates significantly the remaining risks.

4. Best practices

In order for the interlinking of risk management and clinical evaluation not only formally, but actually effectively, the following proven procedures have established themselves in everyday work:

4.1 Frequent stumbling blocks

1. Unclear questions
   are not precisely translated into clinical endpoints (claims on clinical security), the data requirement cannot be clearly derived. Avoid vague formulations.
2. In -transparent traceability
   If there are no clear cross -references in CER and risk management clocks, auditors cannot understand the origin of the results. Rain traceability right from the start.
3. Static documents
   A once created risk management clock or a CER that is not updated regularly fails. Even small design modifications can result in new risks or changed data requirements.
4. Insules instead of interdisciplinary teams
   If clinicists, engineers and regulatory affairs work separately, fractures arise. Plan interdisciplinary reviews with clear responsibilities.
5. Inappropriate choice of route
   The wrong choice between your own studies, equivalence data or performance data leads to unnecessary effort or regulatory inquiries. Make the route decision early on the basis of a transparent evaluation framework.

4.2 Continuous update

• Define Change Control trigger
  , determine which changes (e.g. design updates) automatically trigger an update of risk management and CER.
• Regular review cycles
  arrange at least half -year meetings of all stakeholders to update risk and clinical data. Use checklists so as not to overlook topics.
• Use digital tools
  via automatically well -groomed cross -references link digital tools the clinically relevant risks with the associated clinical endpoints and the corresponding CER chapters. This is the case with seamless traceability without manual effort and auditors can check the entire detection path with just a few clicks.
• Documentation rolls establish
  clear roles for authors, reviewers and releases in both processes. Note metadata such as version, release date and revision history in documents.

4.3 Example: Derivation of end points/claims for clinical security from clinically relevant risks 

Imagine you have a digital infrared earmometer as a product in the product portfolio.

As part of the clinical evaluation of the thermometer, the following clinically relevant residual risks were identified from the risk management fact:

• Old channel irritation or injury
  improper insertion of the probe can lead to pain, microtrauma or, in the worst case, eardrum injuries.
• Cross-contamination
  inadequate cleaning or a lack of one-off protection probe covers can favor the transmission of pathogens (e.g. otitis pathogens) between patients.
• Battery leak / chemical exposure.
  Expiring battery can cause skin irritation or burns if patients or nursing staff come into contact with it.

Further procedure in the clinical evaluation
from these risks derive one or more endpoints in the CEP (e.g. incidence of ear stations, contamination rate for reused probe sleeves) and prove them with suitable evidence (studies, user USABILITY tests, cleaning validation). In this way, make sure that the benefit -risk ratio of your ear thermometer is clearly positive and ensures safe use for patients.

From the clinically relevant risks found in risk management, z. B. the following quantifiable claims result:

• Ear channel
  General End point/measurable parameter : Incidence of ear stations or microtrauma ≤ 0.1 %
  → Claim: "In ≥ 99.9 % of the cases, no irritation (if this data has been collected in the study/studies)
• Cross -contamination
  endpoint/measurable parameter : contamination rate ≤ 1 % according to validated cleaning and disinfectant protocol
  → Claim: "A result of a contamination rate of ≤ 1 % when using the validated cleaning and disinfection procedure." (Data from Studies/Product Register)

Or a common end point/claim would also be possible:

• Safe clinical application with minimal incidence of undesirable incidents -achieved by conformity with EN ISO 109931 (biological security), IEC 60601-1 and IEC 60601-1-2 (electrical security) and IEC 62366-1 (usability):
  -Incortion of ≤ 0.1 % Slight ear stairs
  -contamination rate of ≤ 1 % after Validated cleaning//disinfection protocol
  - documented cases of battery - clever in the customer feedback = 0

5. Conclusion

A consistently networked procedure for risk management and clinical evaluation is the key to an efficient and regulatory correct market launch of medical devices. By specifically transferring identified risks into clinical issues and systematically deriving the clinical data requirement, they create resilient foundations for benefit -risk analyzes and meaningful clinical claims. Regular updates, clear traceability and interdisciplinary cooperation prevent typical stumbling blocks and ensure that both developers and auditors recognize the common thread at all times. Use digital tools and defined change control trigger to keep your processes agile and to meet the growing requirements of the MDR. In this way, they not only lay the foundation for successful approval, but also strengthen the trust of users and named areas in the long term in the safety and performance of their products.

6. How we can help you

We would be happy to support you in making the interface between risk management and clinical evaluation efficiently:

• GAP -Analysis and Audit - Readiness
  We check your risk management acts and clinical evaluation for completeness, traceability gaps and conformity (ISO 14971ISO 14971, MDR) and prepare them specifically for audits.
• Workshops "risk -to -clinic"
  in interactive workshops we define clinically relevant residual risks, derive precise endpoints and formulate quantifiable claims for clinical security.
• Data strategy & route decision-making route decision
  We will advise you on the selection of optimal data sources-your own studies, equivalence data or performance/-/pmcF tests-and support you in study planning or PMCF.
• Regulatory accompaniment
  from the preparation of your named - Audits to the submission: We are at your side when creating the document, review and tracking.

Would you like to know more? Contact us for a free initial talk !